Evidence map›Paper›PMID 33866915›Full record

ArticleDrug delivery2021

Tumor-targeted Gd-doped mesoporous Fe

Shaohui Zheng, Shang Jin, Min Jiao, Wenjun Wang, Xiaoyu Zhou, Jie Xu, Yong Wang, Peipei Dou, Zhen Jin, Changyu Wu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. GdProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  5. Boron and Gadolinium Loaded FeInternational journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shaohui ZhengSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, China.ORCID https://orcid.org/0000-0001-8585-9428
Shang JinSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, China.
Min JiaoSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, China.
Wenjun WangSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, China.
Xiaoyu ZhouSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, China.
Jie XuSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, China.
Yong WangSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, China.
Peipei DouSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, China.
Zhen JinCollege of Medical Engineering, Xinxiang Key Laboratory of Neurobiosensor, Xinxiang Medical University, Xinxiang, Henan , China.
Changyu WuSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, China.
Jingjing LiSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, China.
Xinting GeSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, China.
Kai XuSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, a novel intelligent nanoplatform to integrate multiple imaging and therapeutic functions for targeted cancer theranostics. The nanoplatform, DOX@Gd-MFe

Indexed as

AnimalsAntibiotics, AntineoplasticCell Line, TumorContrast MediaDoxorubicinDrug CarriersDrug Delivery SystemsDrug LiberationGadoliniumMagnetic Iron Oxide NanoparticlesMagnetic Resonance Imaging, InterventionalMiceNeoplasmsAntibiotics, AntineoplasticContrast MediaDoxorubicinDrug CarriersGadoliniumGd dopingmesoporous Fe3O4 NPssynergistic cancer therapyT1/T2 MR imagingTumor targeting

Identifiers

PMID33866915
PMCPMC8079076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.